In a single-arm phase II clinical study (NCT01302496), patients with stage III/IV malignant melanoma were treated with DCs, electroporated with TriMix, and mixed with multiple LAMP-1-fused melanoma-associated tumor mRNAs (TriMixDC-MEL), along with ipilimumab (IPI; CTLA-4 inhibitor) mAb [265]. Here, CTLA4 is linked to neoplasm.